Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Bibliographic Data

ID23346473
AuthorsNick Andrews (0000-0003-4388-1832, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Julia Stowe (0000-0002-3999-6461, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Freja Kirsebom (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Samuel Toffa (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Tim Rickeard (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Eileen Gallagher (0009-0007-9223-5542, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Charlotte Gower (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Meaghan Kall (0000-0001-6971-427X, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Natalie Groves (0000-0002-3832-3484, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Anne-Marie O’Connell (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), David Simons (0000-0001-9655-1656, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Paula B Blomquist (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Asad Zaidi (0000-0002-5250-9576, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Sophie Nash (0000-0002-7717-6982, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Nurin Iwani Binti Abdul Aziz (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Simon Thelwall (0000-0002-0434-2724, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Gavin Dabrera (0000-0003-4606-5945, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Richard Myers (0000-0003-4269-1164, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Gayatri Amirthalingam (0000-0003-2078-0975, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Saheer Gharbia (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Jeffrey C Barrett (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Richard Elson (0000-0001-6350-5274, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Shamez N Ladhani (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Neil Ferguson (0000-0001-8361-2595, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Maria Zambon (0000-0002-8897-7881, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Colin N J Campbell (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Kevin Brown (0000-0002-3238-3750, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Shakita Hopkins (0000-0001-5179-5702, Anna Needs Neuroblastoma Answers), Susan Hopkins (0000-0003-1781-2382, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Meera Chand (0000-0001-9697-0340, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Mary Ramsay (From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un), Jamie Lopez Bernal (0000-0002-1301-5653, From the U.K. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.G., M.K., N.G., A.-M.O., D.S., P.B.B., A.Z., S.N., N.I.B.A.A., S. Thelwall, G.D., R.M., G.A., S.G., R.E., S.N.L., M.Z., C.N.J.C., K.B., S.H., M.C., M.R., J.L.B.), the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (N.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George’s Un)
Year2022
Volume386
Issue16
Pages1532-1546
Publication date2022-04-21
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueNew England Journal of Medicine (JOURNAL)
Journal identifiersISSN: 0028-4793 • E-ISSN: 1533-4406
PublisherMassachusetts Medical Society (PUBLISHER • US)
DOI10.1056/nejmoa2119451
PMID35249272
OpenAlexW4214863616
LanguageEN
Citations received72
References cited24

BACKGROUND: A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines. METHODS: We used a test-negative case-control design to estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. RESULTS: Between November 27, 2021, and January 12, 2022, a total of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all time points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from 20 weeks after two ChAdOx1 nCoV-19 doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks. Among ChAdOx1 nCoV-19 primary course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at 2 to 4 weeks after a BNT162b2 booster before decreasing to 39.6% (95% CI, 38.0 to 41.1) at 10 or more weeks. Among BNT162b2 primary course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at 2 to 4 weeks after a BNT162b2 booster before declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness after a ChAdOx1 nCoV-19 primary course increased to 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks after an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.7 to 62.1) at 5 to 9 weeks. After a BNT162b2 primary course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.1 to 74.6) at 2 to 4 weeks; vaccine effectiveness fell to 64.4% (95% CI, 62.6 to 66.1) at 5 to 9 weeks. CONCLUSIONS: Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.).

Booster (rocketry) · Disease · Immunization · Infectious disease (medical specialty) · Vaccination · Respiratory viral infections research · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy

  • Increased Secondary Attack Rates among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in Japan

    Open Access•Tsuyoshi Ogata, Harumi Tanaka et al.•International Journal of…•2022

  • Covid-19 Infection and Vaccination Among Healthcare Workers in a South African Academic Hospital

    Open Access•Xolelwa Ntsham, Vusumuzi Nkosi et al.•International Journal of…•2025

  • Community members have more impact on their neighbors than celebrities”

    Open Access•Maria Tjilos, Autumn L Tamlyn et al.•BMC Public Health•2023

  • The impact of quality-adjusted life years on evaluating Covid-19 mitigation strategies

    Open Access•Lander Willems, Lander Willem et al.•BMC Public Health•2024

  • Factors That Affect the Covid-19 Pandemic in Summer 2022 Compared to Summer 2021

    Open Access•Marharyta Sobczak, Rafał Pawliczak•International Journal of…•2022

  • Panic in the Pandemic

    Open Access•Thushara Kamalrathne, Ravindu Jayasekara et al.•International Journal of…•2024

  • Assessment of Sars-CoV-2 neutralizing antibody persistence using LFIC

    Open Access•Ana C Montagud, Raúl Moragues et al.•BMC Public Health•2025

  • Correlates of Covid-19 vaccination intentions and opinions about mandates among four groups of adults in South Africa with distinct vaccine intentions

    Open Access•Keren Eyal, Katherine Eyal et al.•BMC Public Health•2023

  • How Did the Covid-19 Pandemic Affect Population Mobility in Taiwan

    Open Access•Shih‐Feng Liu, Hui-Chuan Chang et al.•International Journal of…•2022

  • Delta and Omicron

    Open Access•F Neuberger, Mariana Grgic et al.•BMC Public Health•2022

  • Bibliometric Analysis of Global Scientific Production on Covid-19 and Vaccines

    Open Access•Antônio Rosa de Sousa Neto, Ana Raquel Batista de Carvalho et al.•International Journal of…•2023

  • Social participation and mental health of immunocompromised individuals before and after Covid-19 vaccination–Results of a longitudinal observational study over three time points

    Open Access•Gloria Heesen, Stephanie Heinemann et al.•Frontiers in Psychiatry•2022

  • Effectiveness of Booster Vaccinations on the Control of Covid-19 during the Spread of Omicron Variant in Malaysia

    Open Access•Matthew Tze Jian Wong, Satvinder S Dhaliwal et al.•International Journal of…•2023

  • The role of vaccine status homophily in the Covid-19 pandemic

    Open Access•Elisha B Are, Kiffer G Card et al.•BMC Public Health•2024

  • Acceptance of Seasonal Influenza Vaccine Following Covid-19 Vaccination

    Itay Nitzan, Inbal Akavian et al.•Behavioral Medicine•2022

  • Studying Disease Reinfection Rates, Vaccine Efficacy, and the Timing of Vaccine Rollout in the Context of Infectious Diseases

    Open Access•Elizabeth B Amona, Indranil Sahoo et al.•International Journal of…•2025

  • STEM education in the Global North and Global South

    Open Access•Ronicka Mudaly, Tamirirofa Chirikure•Frontiers in Education•2023

  • Case study of the Beijing 2022 Olympic Winter Games

    Open Access•Da Huo, Ying Shen et al.•Frontiers in Public Health•2023

  • Policies on children and schools during the Sars-CoV-2 pandemic in Western Europe

    Open Access•Antoni Soriano‐Arandes, Antoni Soriano-Arandes et al.•Frontiers in Public Health•2023

  • Omicron Covid-19 variant outcomes and vaccination in non-severe and non-critical patients at admission

    Open Access•Hong Zhao, Wenyi Ye et al.•Frontiers in Public Health•2023

  • Critical national response in coping with Omicron variant in China, Israel, South Africa, and the United States

    Open Access•Manmohan Singh, Jun Jiao et al.•Frontiers in Public Health•2023

  • How to control the spatiotemporal spread of Omicron in the region with low vaccination rates

    Open Access•Chengzhuo Tong, Zhicheng Shi et al.•Frontiers in Public Health•2022

  • Is Endemicity a Solution for the Covid-19 Pandemic? The Four E's Strategy for the Public Health Leadership

    Open Access•Leonardo Villani, Maria Rosaria Gualano et al.•Frontiers in Public Health•2022

  • Covid-19 vaccine response and safety in patients with cancer

    Open Access•Hong Sun, Fengjiao Bu et al.•Frontiers in Public Health•2022

  • Primary healthcare workers’ Covid-19 infection status following implementation of adjusted epidemic prevention and control strategies

    Open Access•Beier Lu, Rongji Ma et al.•Frontiers in Public Health•2023

  • Policy choices for Shanghai responding to challenges of Omicron

    Open Access•Ying Qian, Siqi Cao et al.•Frontiers in Public Health•2022

  • Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated Covid-19 vaccine

    Open Access•Zhifei Chen, Fangqin Xie et al.•Frontiers in Public Health•2025

  • Assessing Vaccination Prioritization Strategies for Covid-19 in South Africa Based on Age-Specific Compartment Model

    Open Access•Chao Zuo, Zeyang Meng et al.•Frontiers in Public Health•2022

  • Willingness and Perceptions Regarding Covid-19 Vaccine Booster Dose in Pakistani Vaccinated Population

    Open Access•Abdul Moeed, Hala Najeeb et al.•Frontiers in Public Health•2022

  • Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection

    Open Access•Huiling Zheng, Shenggen Wu et al.•Frontiers in Public Health•2024

  • An exploration on Covid-19 vaccination motivation patterns from the perspective of the Chaxu culture in metropolis of China

    Open Access•Jiaoling Huang, Zhiyun Jiang et al.•Frontiers in Public Health•2022

  • Exploring attitudes toward Covid-19 vaccinations amongst healthcare workers at a national infectious disease center in Singapore—a cross-sectional study

    Open Access•Victoria Lien, Ying Hao et al.•Frontiers in Public Health•2026

  • Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127

    Open Access•Chengzhuo Tong, Wenzhong Shi et al.•Frontiers in Public Health•2022

  • Frequency of Sars-CoV-2 variants identified by real-time PCR in the Auna healthcare network, Peru

    Open Access•Tamin Ortiz-Gómez, Andrea C Gomez et al.•Frontiers in Public Health•2024

  • Vaccine efficacy against Sars-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines

    Open Access•Lia Reynolds, Cate Dewey et al.•Frontiers in Public Health•2023

  • The role of booster vaccination in decreasing Covid-19 age-adjusted case fatality rate

    Open Access•Cui Zhou, Åsa M Wheelock et al.•Frontiers in Public Health•2023

  • Mathematical modeling of Sars-CoV-2 variant substitutions in European countries

    Open Access•Víctor López de Rioja, Aida Perramon-Malavez et al.•Frontiers in Public Health•2024

  • Relationships between Covid-19 healthcare outcomes and county characteristics in the U.S. for Delta (B.1.617.2) and Omicron (B.1.1.529 and BA.1.1) variants

    Open Access•Alexander A Bruckhaus, Yujia Zhang et al.•Frontiers in Public Health•2023

  • Adherence to Covid-19 preventive measures in Sub-Saharan Africa during the 1st year of the pandemic

    Open Access•Leonard Ngarka, Joseph Nelson Siewe Fodjo et al.•Frontiers in Public Health•2022

  • The Vaccine Efficacy Against the Sars-CoV-2 Omicron

    Open Access•Yuntao Zou, Doudou Huang et al.•Frontiers in Public Health•2022

  • Willingness to vaccinate among adults, and factors associated with vaccine acceptance of Covid-19 vaccines in a nationwide study in Poland between March 2021 and April 2022

    Open Access•Eftychia Kotronia, Magdalena Rosińska et al.•Frontiers in Public Health•2023

  • The pattern from the first three rounds of vaccination

    Open Access•Jian Wu, Xinghong Guo et al.•Frontiers in Public Health•2023

  • Two years of Covid-19 pandemic

    Open Access•Vanessa dos Santos Faiões, Helvécio Cardoso Corrêa Póvoa et al.•Frontiers in Public Health•2022

  • Effectiveness of Sars-CoV-2 vaccines against Omicron infection and severe events

    Open Access•Shangchen Song, Zachary J Madewell et al.•Frontiers in Public Health•2023

  • Covid-19 vaccination roll-outs in eleven small countries within the WHO European region; Lessons learned

    Open Access•Katie Palmer, Leda Nemer et al.•Frontiers in Public Health•2022

  • Perceptions and responses to Covid-19 through wastewater surveillance information and online search behavior

    Open Access•Michio Murakami, Shuhei Nomura et al.•International Journal of Disaster…•2025

  • Mitigation strategies for responding to the Covid-19 pandemic after reopening from the global perspective

    Open Access•Yelin Sun, Gangfeng Zhang et al.•International Journal of Disaster…•2024

  • Factors, enablers and challenges for Covid-19 vaccine development

    Open Access•Jean-Louis Excler, Melanie Saville et al.•BMJ Global Health•2023

  • The compound risk of heat and Covid-19 in New York City

    Open Access•Janelle Knox-Hayes, Juan Camilo Osorio et al.•Local Environment•2023

  • Social media narratives can influence vaccine intentions

    Open Access•Madhav Pokharel, Helen M Lillie et al.•Computers in Human Behavior•2023

  • Vaccine mandates for healthcare workers beyond Covid-19

    Open Access•Alberto Giubilini, Julian Savulescu et al.•Journal of Medical Ethics•2023

  • Covid-19 vaccine boosters for young adults

    Open Access•Kevin Bardosh, Allison Krug et al.•Journal of Medical Ethics•2024

  • Vaccination decisions under risk

    Open Access•Benedicta Hermanns, Johanna Kokot•Theory and Decision•2026

  • Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    Open Access•Catherine Riou, Jinal N Bhiman et al.•PLOS Global Public Health•2024

  • A half-century investigation of police officer line-of-duty deaths

    Michael D White, Khadija Monk et al.•Police Practice and Research•2024

  • Can vaccination intentions against Covid-19 be nudged

    Open Access•Elena Kantorowicz-Reznichenko, Jaroslaw Kantorowicz et al.•Behavioural Public Policy•2022

  • Social Network, Trust, Approval of President Biden, Risk Perception, and Annual Covid-19 Booster Intention

    Open Access•F Hao, Stephen R Neely•Socius Sociological Research for…•2024

  • Navigating Covid-19 Surges

    Open Access•Jie Ying Ng, Milawaty Nurjono et al.•International Journal of…•2024

  • Post-truth and pathways for evaluators

    Open Access•Astrid Brousselle•Evaluation•2024

  • See That Post, Get That Shot

    Xiaobei Chen, Samantha Benavides et al.•Health Communication•2026

  • Disparities and effectiveness of Covid-19 vaccine policies in three representative European countries

    Open Access•Wanzhen Xie, Leiyu Shi et al.•International Journal for Equity…•2024

  • Path dependency of urban resilience to recurring Covid-19 waves

    Open Access•Ningyezi Peng, Xintao Liu•Cities•2025

  • Impact of the Covid-19 vaccination on confusion around vaccination in general

    Open Access•Marine Paridans, Justine Monseur et al.•PLOS Global Public Health•2024

  • Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa

    Open Access•Nigel Garrett, Tarylee Reddy et al.•PLOS Global Public Health•2024

  • Investigation of Covid-19 transmission during the first community outbreak in a remote island population, Falkland Islands, April to June 2022

    Open Access•Alice Wynne, Thomas Bale et al.•PLOS Global Public Health•2024

  • Modelling Covid-19 vaccine breakthrough infections in highly vaccinated Israel—The effects of waning immunity and third vaccination dose

    Open Access•Anyin Feng, Uri Obolski et al.•PLOS Global Public Health•2022

  • The economic impacts of Covid-19 hospitalizations, intensive care unit admissions, and deaths related to overweight and obesity

    Open Access•Adeyemi Okunogbe, Donal Bisanzio et al.•PLOS Global Public Health•2025

  • Moral characteristics predicting Covid ‐19 vaccination

    Open Access•Zher‐wen, Zher‐Wen Zher‐Wen et al.•Journal of Personality•2024

  • Contextual Pathways Linking Cumulative Experiences of Racial Discrimination to Black American Men’s Covid Vaccine Hesitancy

    Open Access•Michael G Curtis, Christopher C Whalen et al.•Journal of Racial and Ethnic…•2023

  • Crises and complexity

    Open Access•Zaruhi Mkrtchyan, Yolanda Moyo et al.•Health Policy and Planning•2025

  • A comparative study of eight Covid-19 protective measures and their impact on Swiss tourists’ travel intentions

    Open Access•Andreas Philippe Hüsser, Timo Ohnmacht•Tourism Management•2023

  • The Impact of Urban Scaling Structure on the Local-Scale Transmission of Covid-19

    Ningyezi Peng, Xintao Liu•Annals of the American…•2024

  • Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

    Jamie Lopez Bernal, Nick Andrews et al.•New England Journal of Medicine•2021

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Sars-CoV-2

    Open Access•Merryn Voysey, Sue Ann Costa Clemens et al.•The Lancet•2021

  • Efficacy and Safety of the mRNA-1273 Sars-CoV-2 Vaccine

    Open Access•Lindsey R Baden, Hana M El Sahly et al.•New England Journal of Medicine•2021

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

    Open Access•Fernando P Polack, Stephen J Thomas et al.•New England Journal of Medicine•2020

  • BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

    Open Access•Noa Dagan, Noam Barda et al.•New England Journal of Medicine•2021

Unique citing works72
Citations per year18
Citation span2022 - 2026 (5)
Citation velocitycurrent
Highly citedNo
Citation typesNeutral: 70
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae